Autosomal dominant polycystic kidney disease with diffuse proliferative glomerulonephritis - an unusual association: a case report and review of the literature
© D'Cruz et al; licensee BioMed Central Ltd. 2010
Received: 4 November 2009
Accepted: 29 April 2010
Published: 29 April 2010
Autosomal dominant polycystic kidney disease is an inherited disorder that is characterized by the development and growth of cysts in the kidneys and other organs. Urinary protein excretion is usually less than 1 g/24 hours in autosomal dominant polycystic kidney disease, and an association of nephrotic syndrome with this condition is considered rare. There are only anecdotal case reports of autosomal dominant polycystic kidney disease associated with nephrotic syndrome, with focal segmental glomerulosclerosis being the most commonly reported histopathological diagnosis. Nephrotic-range proteinuria in the presence of autosomal dominant polycystic kidney disease, with or without an accompanying decline in renal function, should be investigated by open renal biopsy to exclude coexisting glomerular disease. To the best of our knowledge, this is the first case of autosomal dominant polycystic kidney disease with histologically proven diffuse proliferative glomerulonephritis presenting with nephrotic-range proteinuria. No other reports of this could be found in a global electronic search of the literature.
We report the case of a 35-year-old Indo-Aryan man with autosomal dominant polycystic kidney disease associated with nephrotic syndrome and a concomitant decline in his glomerular filtration rate. Open renal biopsy revealed diffuse proliferative glomerulonephritis. An accurate diagnosis enabled us to manage him conservatively with a successful outcome, without the use of corticosteroid which is the standard treatment and the drug most commonly used to treat nephrotic syndrome empirically.
Despite the reluctance of physicians to carry out a renal biopsy on patients with autosomal dominant polycystic kidney disease, our case supports the idea that renal biopsy is needed in patients with polycystic kidney disease with nephrotic-range proteinuria to make an accurate diagnosis. It also illustrates the importance of open renal biopsy in planning appropriate treatment for patients with autosomal dominant polycystic kidney disease with nephrotic-range proteinuria. The treatment for various histological subtypes leading to nephrotic syndrome is different, and in this modern era we should practice evidence-based medicine and should avoid empirical therapy with its associated adverse effects.
In patients with autosomal dominant polycystic kidney disease (ADPKD), urinary protein excretion is usually less than 1 g/24 hours. If proteinuria reaches the nephrotic range, the possibility of another coexistent glomerular disease should always be considered. In such a situation, open renal biopsy is warranted to reach a firm diagnosis. A review of the literature revealed only anecdotal case reports of ADPKD associated with nephrotic syndrome, with focal segmental glomerulosclerosis (FSGS) being the most commonly reported histopathological diagnosis. We report an unusual case of ADPKD with diffuse proliferative glomerulonephritis (DPGN) and nephrotic-range proteinuria. This is the first documented case of ADPKD with DPGN as no other reports of this could be found in a global electronic search of the literature.
A 35-year-old Indo-Aryan man presented with facial puffiness and dyspnea on exertion for two weeks. He denied any history of abdominal pain, fever, dysuria, smoky urine, gross hematuria, sore throat, skin infection, joint pains, skin rash and oral ulcers. He was diagnosed with ADPKD, and his mother also had the disease. A general physical examination revealed his blood pressure was 170/110 mmHg and he had bilateral pitting pedal edema. A systemic examination of our patient was unremarkable except for bilaterally palpable knobby kidneys.
His blood test results showed the following: hemoglobin 136 g/L, total leukocyte count 8200/mm3 (Neutrophils 65%, Lymphocytes 28%, Monocytes 5%, Eosinophils 2%), platelet count 2.5 × 105/mm3, blood urea nitrogen 6.6 mmol/L, serum creatinine 150 μmol/L, serum potassium 3.8 mmol/L, serum albumin 30 g/L and serum cholesterol 7.42 mmol/L. Urine analysis showed 3+ albumin, and 20-25 leukocytes and 8-10 red blood cells per high power field. His 24-hour urinary protein excretion was 4.67 g. Urine culture and throat swab culture were sterile. Blood cultures on two separate occasions were also sterile. Ultrasound analysis of the abdomen of our patient showed an enlarged liver with multiple cysts and both kidneys were enlarged with multiple cysts of varying sizes (in both the cortex and medullary regions). Transthoracic echocardiography was normal and did not reveal any vegetations. Serology for hepatitis B surface antigen and anti-hepatitis C antibodies were non-reactive. Anti-nuclear antibody (ANA) and anti-neutrophil cytoplasmic antibody (ANCA) were shown as negative using the immunofluorescence technique. Anti-streptolysin O (ASO) titer was 350 Todd units. Serum complement (C3) was 70 mg/dL (normal range 75-135 mg/dL) which returned to normal levels at 12 weeks from the time of diagnosis.
The frequency of occurrence of proteinuria in ADPKD ranged from 14 to 34% in non-uremic adults to about 80% in adults with advanced renal failure in the review by Chapman et al. . When present in patients with ADPKD, proteinuria is generally less than 1 g/24 hours. In patients of ADPKD; nephrotic range proteinuria, with or without an accompanying decline in renal function, is unusual and needs to be investigated further to exclude coexisting glomerular disease. Moreover, proteinuria hastens the progression of ADPKD to end-stage renal disease (ESRD) if it is untreated. Patients with established proteinuria have significantly higher mean arterial pressure, large renal volumes, lower creatinine clearances and a more aggressive course. Even microalbuminuric ADPKD patients with hypertension have a significantly higher filtration fraction and larger renal volumes .
The presence of nephrotic-range proteinuria is exceptional in ADPKD, with less than 20 cases having been reported in the literature so far. This may be due in part to the reluctance of nephrologists to perform renal biopsy in these patients, as this usually entails an open renal biopsy. Dalgaard et al.  described three cases of proteinuria >5 g/day in a report of 122 cases with ADPKD. Unfortunately renal biopsy data are not available in this series.
Renal histology in cases of nephrotic-range proteinuria in autosomal dominant polycystic kidney disease patients reported in the literature so far.
First author [Ref. No.] Year
Kida  1972
Focal glomerulosclerosis and/or minimal change disease
Murphy  1990
Montoyo  1992
Dionisio  1993
Contreas  1995
Abe  1985
Shikata  1991
Saxena  1993
Nakahama  1991
Minimal change disease
Kuroki  1995
Minimal change disease
Panisello  1988
Immunoglobulin A nephropathy
Hiura  2006
Immunoglobulin A nephropathy
Licina  1981
Hariharan  1987
Intercapillary diabetic glomerulosclerosis
Villar  1992
Type 1 membranoproliferative glomerulonephritis
Villar  1992
Seyrek  1995
Sar  2007
Diffuse proliferative glomerulonephritis
Glomerular hyperfiltration could play an important role in the development of FSGS and heavy proteinuria in patients with ADPKD. In a histological study of the kidneys of 12 ADPKD patients by Montoyo et al. , interstitial fibrosis and tubular atrophy were found to be the main determinants of the development of chronic renal failure in ADPKD. In a study of 18 cases, Zeier et al.  reported interstitial fibrosis and arteriolar sclerosis as being the most important lesions in kidneys of ADPKD patients, whereas FSGS was observed in less than 5% of the glomeruli.
The index case was a diagnosed case of ADPKD who presented with nephrotic-range proteinuria with active urinary sediment. Open kidney biopsy was consistent with DPGN. This association of ADPKD and DPGN has not been described in the literature so far. Proteinuria is usually less than 3 g/24 hours in more than 75% of patients with DPGN, however it may reach the nephrotic range in 20% of hospitalized patients. Open renal biopsy in our case not only aided our prognostications, but also helped us in reaching a definitive diagnosis. Biopsy report enabled us to obviate the use of corticosteroids in our patient, which is the usual modality of empirical therapy in patients with nephrotic syndrome.
To the best of our knowledge, our patient was the first ADPKD patient with nephrotic syndrome caused by post-streptococcal DPGN. It might have been a chance association, as both DPGN and ADPKD are common in the general population, but nephrologists should be aware of this potential association. Our case again illustrates the importance of open renal biopsy in patients with polycystic kidney disease with nephrotic-range proteinuria, as the treatment for various histopathological subtypes leading to nephrotic syndrome is different and in this modern era we should practice evidence-based medicine. It also illustrates a way of avoiding empirical therapy.
Clinicians are reluctant to perform renal biopsy in patients of ADPKD as it entails an open renal biopsy which requires the involvement of a surgeon. However, our case reinforces the need for renal biopsy in patients with polycystic kidney disease presenting with nephrotic-range proteinuria to exclude any coexisting glomerular disease, and to reach an accurate diagnosis. It also illustrates the importance of open renal biopsy in patients with ADPKD and nephrotic-range proteinuria in order to plan appropriate treatment. Treatment for various histopathological subtypes leading to nephrotic syndrome is different. Corticosteroids are beneficial in some conditions whereas they may not be of any use in other cases. A lesson to be learnt from our case is that an open renal biopsy should be carried out in all patients with ADPKD presenting with nephrotic syndrome to make an accurate diagnosis. Reaching a firm diagnosis based on histopathology and immunofluorescence studies will help the physician to give appropriate treatment in the form of corticosteroids and/or cytotoxic agents, if indicated, and to avoid empirical therapy with these potentially toxic agents and to avoid their possible adverse effects.
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
- Chapman AB, Johnson AM, Gabow PA, Schrier RW: Overt proteinuria and microalbuminuria in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 1994, 5: 1349-1354.PubMedGoogle Scholar
- Dalgaard OZ: Bilateral polycystic disease of kidney. A follow up of two hundred and eighty-four patients and their families. Acta Med Scand. 1957, 328: 1-255.Google Scholar
- Contreas G, Mercado A, Pardo V, Vaamonde C: Nephrotic syndrome in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 1995, 6: 1354-1359.Google Scholar
- Montoyo C, Martinez MA, Campo C, Mazuecos A, Andres A, Praga M: Nephrotic syndrome and focal glomerulosclerosis in adult polycystic kidney disease. Nephron. 1992, 61: 106-110. 10.1159/000186845.View ArticlePubMedGoogle Scholar
- Zeier M, Geberth S, Ritz E, Jaeger T, Waldherr R: Adult dominant polycystic disease. Clinical problems. Nephron. 1988, 49: 177-183. 10.1159/000185052.View ArticlePubMedGoogle Scholar
- Kida H, Nakamoto Y, Shinoda A: Case of polycystic kidney with nephrotic syndrome. Naika Int Med. 1972, 29: 168-172.Google Scholar
- Murphy G, Tzamaloukas AH, Listrom MB, Gibel LJ, Meleg Smith S, Gardner KD: Nephrotic syndrome and rapid renal failure in autosomal dominant polycystic kidney disease. Am J Nephrol. 1990, 10: 69-72. 10.1159/000168057.View ArticlePubMedGoogle Scholar
- Dionisio P, Bergia R, Caramello E, Lange A, Bajardi P: A contribution to nephrotic syndrome and focal glomerulosclerosis in a patient with adult polycystic kidney disease. Nephron. 1993, 64: 318-319. 10.1159/000187339.View ArticlePubMedGoogle Scholar
- Abe R, Yamaguchi K: A case of polycystic kidney associated with membranous nephropathy. Kidney Dial. 1985, 9: 389-Google Scholar
- Shikata K, Makino H, Ota Z: A membranous nephropathy associated with adult polycystic kidney disease. Clin Nephrol. 1991, 36: 223-227.PubMedGoogle Scholar
- Saxena S, Hotchandani RK, Bhuyan UN, Agarwal SK, Tiwati SC, Dash SC: Membranous glomerulonephritis associated with autosomal dominant polycystic kidney disease. Nephron. 1993, 65 (2): 316-317. 10.1159/000187497.View ArticlePubMedGoogle Scholar
- Nakahama H, Inoue T, Kakihara M, Takama T, Mikami H, Orita Y, Kamada T: A case of polycystic kidney disease with nephrotic syndrome. Urol Int. 1991, 46: 77-78. 10.1159/000281782.View ArticlePubMedGoogle Scholar
- Kuroki A, Honda H, Kobayashi K, Tossuka D, Sugisaki T, Soejima K: A case of autosomal dominant polycystic kidney disease complicated by minimal change nephrotic syndrome. Clin Nephrol. 1995, 43: 131-132.PubMedGoogle Scholar
- Panisello JM, Matinez-Vea A, Garcia C, Carrera M, Oliver JA, Richart C: IgA nephropathy and polycystic kidney disease. Am J Nephrol. 1988, 8: 477-478. 10.1159/000167662.View ArticlePubMedGoogle Scholar
- Hiura T, Yamazaki H, Kawabe S, Ueno M, Nishi S, Miyamura S: Nephrotic syndrome and IgA nephropathy in polycystic kidney disease. Clin Exp Nephrol. 2006, 10 (2): 136-139. 10.1007/s10157-005-0403-6.View ArticlePubMedGoogle Scholar
- Licina MG, Alder S, Bruns FJ: Acute renal failure in a patient with adult polycystic kidney disease. JAMA. 1981, 245: 1664-1665. 10.1001/jama.245.16.1664.View ArticlePubMedGoogle Scholar
- Hariharan S, Date A, Jacob CK: Adult polycystic kidney disease with diabetic intercapillary glomerulosclerosis. J Diabet Complications. 1987, 1: 32-33. 10.1016/S0891-6632(87)80024-7.View ArticlePubMedGoogle Scholar
- Villar MT, Bass P, Dewhurst G, Theaker JM, Dathan JR: Autosomal dominant polycystic kidney disease complicated by glomerulonephritis. Nephron. 1992, 62: 226-228. 10.1159/000187038.View ArticlePubMedGoogle Scholar
- Seyrek N, Paydas S, Akoglu E, Tuncer I, Sagliker Y: Autosomal dominant polycystic kidney disease and mesangioproliferative glomerulonephritis. Nephron. 1995, 71 (2): 232-10.1159/000188721.View ArticlePubMedGoogle Scholar
- Sar F, Taylan I, Kutlu C, Caymaz MS, Tatli E, Kazancioglu R: Amyloidosis in a patient with autosomal dominant polycystic kidney disease and tuberculosis: a case report. Int Urol Nephrol. 2007, 39 (2): 655-659. 10.1007/s11255-006-9052-2.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.